PONVORY
Ponvory (ponesimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. The medication is used to manage various stages of the disease, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It serves as a therapeutic option for adult patients requiring treatment for these specific relapsing forms of MS.
How PONVORY Works
Ponesimod functions as a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to its target receptor. This binding action blocks the capacity of lymphocytes to egress from the lymph nodes, which reduces the total number of lymphocytes circulating in the peripheral blood. While the exact mechanism is unknown, the drug's therapeutic effect in MS may involve the reduction of lymphocyte migration into the central nervous system.
Details
- Status
- Prescription
- First Approved
- 2021-03-18
- Routes
- ORAL
- Dosage Forms
- TABLET
PONVORY Approval History
What PONVORY Treats
3 indicationsPONVORY is approved for 3 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Clinically isolated syndrome
- Relapsing-remitting multiple sclerosis
- Active secondary progressive multiple sclerosis
Drugs Similar to PONVORY
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PONVORY FDA Label Details
ProIndications & Usage
FDA Label (PDF)PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
PONVORY Patents & Exclusivity
Patents (500 active)
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.